Doxycycline patent?

Doxycycline – a tetracycline‑class antibiotic that first hit the market in the early 1970s – has been the subject of a large number of patents over the decades. Below is a quick snapshot of the most important ones, what they cover, and their current status.

Bottom line – The original “doxycycline” patents filed by Pfizer in the 1970s–80s expired in the 1990s. Generic manufacturers have been producing the drug for decades. However, newer patents (e.g., sustained‑release or combination products) can still be in force, which is why you occasionally see branded versions like Vibramycin® (generic), Cipro‑style extended‑release forms, or doxycycline‑based combo pills for acne or Lyme disease.

What’s the practical takeaway?

• Generic doxycycline is widely available and inexpensive. The core drug is no longer under patent protection, so most formulations you see in the U.S. pharmacy are generics.
• Specialty formulations (e.g., extended‑release tablets, doxycycline hyclate capsules, topical gels for acne) may still be covered by patents that restrict how the product can be sold or manufactured. These are typically sold under brand names and are more expensive.
• New indications (e.g., doxycycline for acne, rosacea, or Lyme disease) can be patented separately. If a company wants to claim a new therapeutic use, they must file a “use” patent, which can last until 20 years from filing. Many of those claims are still in force, giving companies a temporary monopoly on that specific indication.

How to find the patent you need

Tip: If you’re a clinician or researcher looking for a specific formulation, look up the patent family to see all related documents – sometimes a single invention is protected by multiple patents in different countries.

Quick FAQ

If you have a specific patent number, use case, or need help navigating the database, just let me know!